ARGX.US argenx NV ADR

Healthcare Biotechnology USA Stocks
972.58 USD
Close of Nov 13, 2026
661.85 1,073
Market cap
USD 61.2B
P/E
33.7x
P/B
7.33x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ARGX.US undervalued?

Graham number

The Graham number of argenx NV ADR cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

argenx NV ADR fundamental analysis

No fundamental analysis for argenx NV ADR yet.

argenx NV ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About argenx NV ADR

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis …

Full company profile